临床试验/NCT01783834

NCT01783834已完成2 期

Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients With Advanced Non-small Cell Lung Cancer

Gachon University Gil Medical Center1 个研究点分布在 1 个国家目标入组 95 人开始时间: 2008年2月最近更新: 2016年2月11日

适应症

干预措施

试验速览

阶段: 2 期
状态: 已完成
发起方: Gachon University Gil Medical Center
入组人数: 95
试验地点: 1
主要终点: Overall response rate

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

To compare the efficacy of gefitinib versus pemetrexed as second-line chemotherapy for patients with previous treated non-small cell lung cancer

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Cells pathologically diagnosed as histological or radical surgery or radiation therapy is not possible stage IIIB and stage IV non-small-cell lung cancer patients
•second line
•Patients with normal liver function and renal function

排除标准

•Patients with severe acute infection requiring antibiotic therapy
•Patients who have received treatment in other areas of cancer within 5 years
•During pregnancy and lactation patients

研究组 & 干预措施

pemetrexed

Active Comparator

pemetrexed

干预措施: Pemetrexed (Drug)

gefitinib

Active Comparator

gefitinib

干预措施: Gefitinib (Drug)

结局指标

主要结局

Overall response rate

时间窗: 5 years

次要结局

Progression free survival(5years)

研究者

发起方

Gachon University Gil Medical Center

申办方类型

Other

责任方

Principal Investigator

主要研究者

Eun Kyung Cho

professor

Gachon University Gil Medical Center

研究点 (1)

Loading locations...

相似试验

已完成

2 期

A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)Carcinoma, Non Small Cell Lung

NCT01469000Eli Lilly and Company195

Unknown

2 期

Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer PatientsToxicityNon-small Cell Lung Cancer

NCT01192243Fudan University68

Unknown

3 期

A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.Completely Resected NSCLC With Common EGFR Mutations

NCT03381066Yonsei University225

已完成

2 期

A Phase II Study of Pemetrexed Plus Gemcitabine for Metastatic/Recurrent Head and Neck Cancer (HNSCC)Head and Neck Cancer

NCT00589667Memorial Sloan Kettering Cancer Center26

终止

2 期

Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck CancerHead and Neck Cancer

NCT00394147Fox Chase Cancer Center17